The Evolving Role of PCSK9 Inhibitors in LDL-C Management

How are the 2026 guideline updates and emerging therapies reshaping lipid care? In this ACC CardiaCast episode, join expert faculty Michael Blaha, MD, MPH, and Ann Marie Navar, MD, PhD, as they break down the latest developments, including: Key updates from the 2026 ACC/AHA dyslipidemia guidelines and what they mean for clinical practice Compelling trial data on PCSK9 inhibitors and their role in helping patients achieve lipid goals A closer look at available therapies, including the newly approved injectable lerodalcibep‑liga Real‑world challenges and barriers associated with injectable PCSK9 inhibitors The next wave of innovation: oral PCSK9 inhibitors, with emerging data on enlicitide and laroprovstat Tune in for expert insights on where lipid management is headed and how to stay ahead in clinical care. #CardiaCast #Dyslipidemia #Cardiology #LipidManagement #PCSK9